Eton Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Mar 19, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 19, 2026

ETON$64.35+14.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

(in thousands, except share and per share amounts)

	December 31,	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$25,942	$14,936
Accounts receivable, net	11,757	5,361
Inventories, net	15,419	15,232
Prepaid expenses and other current assets	7,463	5,492
Total current assets	60,581	41,021
Property and equipment, net	326	34
Intangible assets, net	30,878	34,881
Operating lease right-of-use assets, net	310	175
Other long-term assets, net	19	12
Total assets	$92,114	$76,123
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$10,976	$4,167
Current portion of long-term debt, net of discount	8,789	—
Accrued Medicaid rebates	9,317	6,866
Accrued liabilities	9,408	8,914
Total current liabilities	38,490	19,947
Long-term debt, net of discount and including accrued fees	21,769	29,811
Operating lease liabilities, net of current portion	460	107
Other long-term liabilities	5,241	1,830
Total liabilities	65,960	51,695
Commitments and contingencies (Note 16)
Stockholders’ equity
Common stock, $0.001 par value; 50,000,000 shares authorized; 27,047,061 and 26,709,084 shares issued and outstanding at December 31, 2025 and 2024, respectively	27	27
Additional paid-in capital	138,621	132,294
Accumulated deficit	(112,494)	(107,893)
Total stockholders’ equity	26,154	24,428
Total liabilities and stockholders’ equity	$92,114	$76,123

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.